Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New migraine pill lasmiditan shows promise in Real-World study

NCT ID NCT05903040

Symptom relief Sponsor: University of Florence Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how well and how safely lasmiditan works for treating migraine attacks. One hundred adults with migraine took lasmiditan tablets (50, 100, or 200 mg) when they had an attack. Researchers measured how many people were pain-free after 2 hours and tracked any side effects. The goal was to see if lasmiditan is a good option for quick migraine relief in everyday use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lasmiditan (oral tablet, 50-100-200 mg)
What this could lead to
If successful, this could confirm lasmiditan as a well-tolerated option for stopping migraine pain quickly.
What could go wrong
This is a small, completed observational study (100 people) without a placebo group, so results may not prove effectiveness compared to no treatment or other drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Jun 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Multicentric study on patients attending the outpatient clinic of Italian Headache centres who meet criteria for lasmiditan use for acute migraine treatments.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III). At least 3 MMDs * Good compliance to study procedures * Availability of headache diary at least of the preceding months before enrollment Exclusion Criteria: * Subjects with contraindications for use of ditans; * Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments; * medical comorbidities that could interfere with study results; * Pregnancy and breastfeeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Headache Headache Disorders, Secondary migraine disorder migraine with aura migraine without aura Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic migraine Migraine Migraine with aura Migraine without aura

Contacts and locations

Locations

  • IRCCS National Neurological Institute "C. Mondino" Foundation

    Pavia, 27100, Italy

  • SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi

    Florence, 50134, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.